Last reviewed 2026-05-27 · How we verify

SCR-6920 capsule

Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

SCR-6920 capsule is a Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd.. It is currently in Phase 1 development. Also known as: PRMT5 inhibitor.

SCR-6920 capsule is a small molecule intervention being studied in a Phase I clinical trial for the treatment of advanced malignant tumors, including solid tumors and non-Hodgkin lymphoma. The trial, SIM1907-04-PRMT5-101, is being conducted by Jiangsu Simcere Pharmaceutical Co., Ltd. to investigate the safety and tolerability of SCR-6920 capsule.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SCR-6920 capsule
Also known as	PRMT5 inhibitor
Sponsor	Jiangsu Simcere Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SCR-6920 capsule CI brief — competitive landscape report
SCR-6920 capsule updates RSS · CI watch RSS
Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about SCR-6920 capsule

What is SCR-6920 capsule?

SCR-6920 capsule is a Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd..

Who makes SCR-6920 capsule?

SCR-6920 capsule is developed by Jiangsu Simcere Pharmaceutical Co., Ltd. (see full Jiangsu Simcere Pharmaceutical Co., Ltd. pipeline at /company/jiangsu-simcere-pharmaceutical-co-ltd).

Is SCR-6920 capsule also known as anything else?

SCR-6920 capsule is also known as PRMT5 inhibitor.

What development phase is SCR-6920 capsule in?

SCR-6920 capsule is in Phase 1.

Manufacturer: Jiangsu Simcere Pharmaceutical Co., Ltd. — full pipeline
Also known as: PRMT5 inhibitor

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing